-
SpeichernDas Eingabefeld wird
gespeichert wenn Sie das Feld
verlassen oder hier klicken.↓
Börse Börse FrankfurtEURSymbol 1FG-
FibroGenBörse Börse FrankfurtEURSymbol 1FG
-
FIBROGEN INCBörse Börse StuttgartEURSymbol 1FG
-
FIBROGEN INCBörse Quotrix System der Börse DüsseldorfEURSymbol 1FG
-
FIBROGEN INCBörse Börse DüsseldorfEURSymbol 1FG
-
FIBROGEN INCBörse Tradegate System der Deutsche Börse AG (60%)EURSymbol 1FG
-
ISIN US31572Q8087 WKN: A12EZ0USDSymbol FGEN
-
MXN
-
USD
-
Symbol 1FG
Währung
EUR
Börse
Börse Frankfurt Zeitzone: Europe/London
Firmenname
FibroGen, Inc
Marktkapitalisierung
3.313.058.144 (+- 53%)
Die einen sagen so, die anderen so... Es gibt 2 Datenquellen:
5.071.116.288 oder 1.555.000.000
Mitarbeiter
549 (+- 3%)
Die einen sagen so, die anderen so... Es gibt 2 Datenquellen:
531 oder 566 Mitarbeiter
KGV
85.04
EBITDA 49.346.000
Buchwert 4.97
FibroGen underperformed den DAX um -53 % vom 19.11.2014 bis 16.07.2021
Die letzten Quartalsergebnisse Erwarteter Gewinn je Aktie beim aktuellen Wert von 16,92 EUR +7,25%
Entdecke die 6 ETFs in denen FibroGen, Inc am höchsten gewichtet ist Insgesamt in 7 ETFs enthalten
Dir gefallen die Informationen zu FibroGen?
Galue bleibt auch in Zukunft kostenfrei und ungesponsort. Wenn Ihr meine Arbeit unterstützen möchtet, dann eröffnet gerne ein kostenloses und unverbindliches Depot bei Trade Republic mit der Möglichkeit kostenlos Aktien zu besparen. Wenn du das über meinen Link machst, bekommst du und ich bei deinem ersten Wertpapierkauf 15 von Trade Republic geschenkt:
Zu Trade Republic
Dir gefallen die Informationen zu FibroGen?
Galue bleibt auch in Zukunft kostenfrei und ungesponsort. Wenn du meine Arbeit unterstützen möchtest, dann eröffne ein kostenloses und unverbindliches Depot bei BUX Zero mit der Möglichkeit kostenlos US-Aktien und für einen Euro viele weitere Aktien aus Deutschland, Belgien, Niederlande, sterreich oder UK zu kaufen. Wenn du das über meinen Link machst, bekommen wir beide eine gratis Aktie geschenkt:
Zu BUX Zero
Dir gefallen die Informationen zu FibroGen?
Galue bleibt auch in Zukunft kostenfrei und ungesponsort. Wenn Ihr meine Arbeit unterstützen möchtet, dann eröffnet gerne ein mindestens 3 Jahre lang kostenloses Depot bei der comdirect. Wenn du das über diesen Link machst unterstützt du auch meine Tochter Zoe, da es Ihr Juniordepot ist. Sie erhält 20 und bei einem aktiven ETF- oder Aktien-Sparplan bleibt dein Depot auch danach kostenfrei:
Zur Comdirect
Dir gefallen die Informationen zu FibroGen?
Galue bleibt auch in Zukunft kostenfrei und ungesponsort. Wenn du meine Arbeit unterstützen möchtest, dann eröffne gerne ein kostenloses und unverbindliches Depot bei der ING Diba. Ich erhalte 20 wenn du daraufhin dann zum Beispiel einen Aktien-Sparplan anlegst oder etwas kaufst:
Zur ING Diba
39 News & Informationen zur FibroGen Aktie
FibroGen To Report Second Quarter 2021 Financial Results
SAN FRANCISCO, July 29, 2021 (GLOBE NEWSWIRE) — FibroGen, Inc. FGEN will announce its second quarter 2021 financial results on Monday, August 9 after the
What's Next for FibroGen After an FDA Vote Against Its Anemia Drug?
FDA approval of roxadustat seems unlikely.
Were Hedge Funds Right About FibroGen Inc (FGEN)?
In this article we will check out the progression of hedge fund sentiment towards FibroGen Inc (NASDAQ:FGEN) and determine whether it is a good investment…
The Week Ahead In Biotech (July 25-31): Big Pharma Earnings, Iterum FDA Decision, Alzheimer's Conference, IPOs and More
Biotech stocks rebounded in the week ended July 23, thanks to the broader market strength. The sector also benefitted from the optimism that was s…
Insperity Inc (NSP) Fell Out Of Favor With Hedge Funds
We know that hedge funds generate strong, risk-adjusted returns over the long run, therefore imitating the picks that they are collectively bullish on…
FibroGen : Eluminex Biosciences Exclusively Licenses FibroGen's Biosynthetic Cornea Technology and Recombinant Collagen III Platform (Form 8-K)
Eluminex Biosciences Exclusively Licenses FibroGen's Biosynthetic Cornea Technology and Recombinant Collagen III Platform
… | July 20, 2021
U.S. stocks lower at close of trade; Dow Jones Industrial Average down 0.86% By Investing.com
U.S. stocks lower at close of trade; Dow Jones Industrial Average down 0.86%
Moderna, State Street rise; FibroGen, Marten Transport fall
Stocks that traded heavily or had substantial price changes Friday: Moderna, State Street rise; FibroGen, Marten Transport fall
Mid-Afternoon Market Update: Dow Tumbles Over 200 Points; Aehr Test Systems Shares Spike Higher
Toward the end of trading Friday, the Dow traded down 0.63% to 34,766.06 while the NASDAQ fell 0.47% to 14,475.13. The S&P also fell, dropping…
Here's Why FibroGen Stock Is Plunging Today
An FDA advisory committee made it clear that they don't want the agency to approve roxadustat due to safety concerns.
FibroGen Plunges As FDA Panel Rejects Drug For Anemia Linked To Kidney Disease By Investing.com
FibroGen Plunges As FDA Panel Rejects Drug For Anemia Linked To Kidney Disease
Mid-Morning Market Update: Markets Down; Kansas City Southern Earnings Miss Views
Following the market opening Friday, the Dow traded down 0.41% to 34,844.89 while the NASDAQ fell 0.30% to 14,499.54. The S&P also fell, dropping 0.30% …
Stocks That Hit 52-Week Lows On Friday
On Friday morning, 68 companies hit new 52-week lows.
Points of Interest: TotalEnergies (NYSE:TTE) was the biggest company by market cap to …
FibroGen (FGEN) Roxadustat Fails to Win FDA Advisory Panel Vote
FibroGen (FGEN) is seeking approval for roxadustat as potential treatment of anemia of chronic kidney disease in the United States. Stock down on unfavorable advisory committee outcome.
Futures Rebound As Op-Ex Gamma Trapdoor Looms
ZeroHedge – On a long enough timeline, the survival rate for everyone drops to zero
The Daily Biotech Pulse: Moderna To Join S&P 500 Index, Thumbs Down For FibroGen's Anemia Drug, Corvus Shelves COVID Study
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Ju…
FibroGen Stock Craters After Roxadustat Setback, But There Is A Silver Lining
Yesterday, the U.S. FDA voted not to approve Roxadustat for the treatment of anemia due to chronic kidney disease in adult patients.
Pre-market Movers: IO, AEHR, DTSS, MRNA, FGEN…
The following are some of the stocks making big moves in Friday's pre-market trading (as of 4.24 A.M. EDT)..
Pre-market Movers: IO, AEHR, DTSS, MRNA, FGEN…
(RTTNews) – The following are some of the stocks making big moves in Friday's pre-market trading (as of 4.24 A.M. EDT). In the Green ION Geophys…
FibroGen Announces Outcome Of FDA Advisory Committee Review Of Roxadustat For Treatment Of Anemia Of Chronic Kidney Disease
SAN FRANCISCO, July 15, 2021 (GLOBE NEWSWIRE) — FibroGen, Inc. FGEN today announced that the U.S. Food and Drug Administration (FDA) Cardiovascular and Renal
FibroGen stock trading halted ahead of FDA AdCom meet for roxadustat (NASDAQ:FGEN)
FibroGen (FGEN) shares halted for trading ahead of a decision by FDA Advisory Committee for the new drug application for roxadustat.Roxadustat is developed in partnership with…
What 3 FibroGen Analysts Are Expecting From Thursday's Roxadustat Adcom Verdict
FibroGen, Inc. (NASDAQ:FGEN) has a key catalyst Thursday when FDA's Cardiovascular and Renal Drugs Advisory Committee will issue its recommend…
Is FibroGen Stock A Buy Going Into Roxa AdCom? (NASDAQ:FGEN)
FGEN stock has been on a long-term downward cycle since peaking in 2018, mainly because of complications/miscommunications related to its lead asset, Roxa's, clinical data.
FibroGen Appoints John Hunter, Ph.D. As Chief Scientific Officer
SAN FRANCISCO, July 12, 2021 (GLOBE NEWSWIRE) — FibroGen, Inc. FGEN announced the appointment of John Hunter, Ph.D., to the position of Chief Scientific
The Week Ahead In Biotech: Adcom Test Awaits FibroGen, Data Readouts, IPOs In The Mix
Biopharma stocks closed the holiday-shortened week lower amid a lack of any significant news flow. On the drug approval front, Provention Bio, In…
EDGAR Filing Documents for 0001564590-21-034630
Any idea why Fibrogen (NASDAQ: FGEN) tanked 10% today from premarket after receiving a positive recommendation on it's key drug? : stocks
“European regulators issued a positive recommendation on FibroGen ‘s key drug roxadustat, which has had major setbacks in its path to approval in …
Fibrogen shares rise 6% on positive CHMP opinion for roxadustat (NASDAQ:FGEN)
Fibrogen (FGEN)perks up 6% premarketafter announcing that the EMA's Committee for Medicinal Products for Human Use ((CHMP)) has adopted positive opinion for Evrenzo (roxadustat) for…
FibroGen is facing a milestone this week: Mizuho (NASDAQ:FGEN)
Fibrogen <> is awaiting a key decision on its oral small molecule inhibitor Roxadustat as the European Medicines Agency ((EMA)) is set to decide on its approval for…
Parent Project Muscular Dystrophy Hosts 2021 Virtual Annual Conference
HACKENSACK, N.J., June 21, 2021 /PRNewswire/ — Parent Project Muscular Dystrophy (PPMD) , a nonprofit organization leading the fight to end Duchenne
Glancy Prongay & Murray LLP : a Leading Securities Fraud Law Firm, Announces the Filing of a Securities Class Action on Behalf of FibroGen Inc. (FGEN) Investors
Shareholders with $100,000 losses or more are encouraged to contact the firm
… | April 14, 2021
FGEN CLASS ACTION ALERT: Kessler Topaz Meltzer & Check, LLP Announces A Securities Fraud Class Action Lawsuit Filed Against FibroGen, Inc.
RADNOR, Pa., April 14, 2021 /PRNewswire/ — The law firm of Kessler Topaz Meltzer & Check, LLP announces that a securities fraud class action lawsuit has been
SHAREHOLDER ALERT: FibroGen, Inc. (FGEN) Officers And Directors Under Investigation For False Statements And Insider Trading
SAN FRANCISCO, April 14, 2021 /PRNewswire/ — Schubert Jonckheer & Kolbe LLP is investigating potential derivative claims on behalf of shareholders of
BREAKING NOTICE: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages FibroGen, Inc. Investors With Losses To Secure Counsel Before Important Deadline – FGEN
NEW YORK, April 13, 2021 /PRNewswire/ —
WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on
Gainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against FibroGen, Inc. (FGEN)
NEW YORK, April 13, 2021 — Gainey McKenna & Egleston announces that a class action lawsuit has been filed against FibroGen, Inc. in the United States District Court for the Northern…
FibroGen (FGEN) DMD Drug Pamrevlumab Gets FDA's Fast Track Tag
The FDA bestows a Fast Track designation to FibroGen's (FGEN) anti-CTGF antibody, pamrevlumab, to treat patients with Duchenne muscular dystrophy. Shares up.
FibroGen: Pamrevlumab Gets FDA's Fast Track Designation To Treat Duchenne Muscular Dystrophy
(RTTNews) – Biotech company FibroGen Inc. (FGEN) announced Monday that the U.S. Food and Drug Administration has granted Fast Track designation fo…
COVID-19 Creating Growth Opportunities for Respiratory Drugs Market; Market to Cross USD 25,500 million by the End of 2027 Due to Soaring Burden of Chronic Respiratory Diseases Worldwide
New York, Jan. 12, 2021 (GLOBE NEWSWIRE) — With availability of limited preventive or therapeutic interventions for respiratory viruses resulting in …
Primecap Curbs Holdings of Cree, BioMarin Pharmaceutical
Primecap Curbs Holdings of Cree, BioMarin Pharmaceutical, Stocks: CREE,BMRN,FGEN,LLY,ADBE,MSFT,BIIB,AMGN, PRIMECAP Management, release date:Jan 08, 2021